Home Tags Antibody

Tag: antibody

EORTC/GIMEA

EORTC/GIMEA Trial Does Not Show Benefits for Older AML Patients

Results of a randomized phase III trial evaluating the efficacy and toxicity of sequential gemtuzumab ozogamicin (GO) and standard chemotherapy provides no benefit in...
CPhl worldwide

CPhI Report Sees ADCs as a Key Driver of Tomorrow’s Healthcare

In the first section of the 2013 annual report and industry expert panel, analysts at CPhI Worldwide and CPhI Pharma Evolution describe how they expect that antibody-drug conjugates or ADCs will become a major product group within the oncology market.

Study Shows Combination of Epratuzumab and Rituximab in Newly Diagnosed Follicular...

The combination of epratuzumab, a humanized anti CD-22 monoclonal antibody, and rituximab (Rituxan®/Genentech; MabThera®/Roche), as a front-line therapy of patients with newly diagnosed follicular lymphoma (FL), produced...

AMF-1c-120 Targets and Binds to Tumors in a Very Localized and...

Results of recent pre-clinical studies with AMF-1c-120 (Amorfix Life Sciences, Ltd) shows that this proprietary anti-ovarian cancer antibody, when administered to live animals, targets and binds to tumors in a very localized and concentrated manner. This is a significant finding because it shows that the antibody retains its tumor-specific binding in vivo.

Anti-CD22 Monomethyl Auristatin Antibody-drug Conjugate Offers Potential Treatment for Non-Hodgkins Lymphoma

Antibody-drug conjugates (ADCs) are target-specific anticancer agents consisting of cytotoxic drugs covalently linked to a monoclonal antibody. They allow specific targeting of drugs to neoplastic...

Total Antibody Quantification for MMAE-Conjugated Antibody-Drug Conjugates: Impact of Assay Format...

The use of antibody drug conjugates (ADCs) as targeted chemotherapies has successfully entered clinical practice and holds great promise. ADCs consist of an antibody...

The Analytical and Bioanalytical Technologies for Characterizing Antibody-drug Conjugates

Antibody-drug conjugates (ADCs) require multiple assays for analytical and bioanalytical characterization due to their heterogeneous and dynamic nature. These assays can help address questions...

Design and Efficacy of Antibody-drug Conjugates in Oncology

The use of antibody drug conjugates (ADCs) as targeted chemotherapies has successfully entered clinical practice and holds great promise. ADCs consist of an antibody...

Sanofi-Aventis In-licenses Therapeutic Antibody for the Treatment of Solid Cancers From...

Earlier this month French pharmaceutical giant Sanofi-aventis acquired an exclusive world-wide license to one of Oxford BioTherapeutics’ internal preclinical antibody programs. Sanofi-aventis intends to...

FEATURED RESOURCES